WO2008006187A2 - Protein complexes for prevention and treatment of diseases with angiogenesis disorders - Google Patents

Protein complexes for prevention and treatment of diseases with angiogenesis disorders Download PDF

Info

Publication number
WO2008006187A2
WO2008006187A2 PCT/BY2007/000002 BY2007000002W WO2008006187A2 WO 2008006187 A2 WO2008006187 A2 WO 2008006187A2 BY 2007000002 W BY2007000002 W BY 2007000002W WO 2008006187 A2 WO2008006187 A2 WO 2008006187A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein complex
diseases
factors
angiogenic
autoantibodies
Prior art date
Application number
PCT/BY2007/000002
Other languages
French (fr)
Other versions
WO2008006187A3 (en
Inventor
Aleksey M. Olovnikov
Oleg N. Darashkevitch
Eugeny I. Goufman
Original Assignee
Legeev, Yury V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legeev, Yury V. filed Critical Legeev, Yury V.
Publication of WO2008006187A2 publication Critical patent/WO2008006187A2/en
Publication of WO2008006187A3 publication Critical patent/WO2008006187A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention is related to the medical field, and in particular, to protein complexes and the application thereof for the correction of autoimmune processes in human or animal bodies and also to a biochemical research for discovering the biochemical mechanisms of progressing diseases with angiogenesis disorders
  • Angiogenesis is a process of formation of new vessels that is inherent to various activities of normal human or animal bodies (Folkman, J , Cancer Research, 46 467473 (1986) Angiogenesis is most strongly characteristic of such processes as reproduction, embryogenesis and wound healing Although the molecular mechanisms of angiogenesis
  • the positive regulators or pro-angiogenic factors include as follows members of family of fibroblast growth factors (FGF), in particular, basic fibroblast growth factor (bFGF), fibroblast growth factor-2 (FGF-2) and keratinocyte growth factor (KGF), 0 members of family of vascular endothelial growth factors, in particular, placental growth factor
  • FGF fibroblast growth factors
  • bFGF basic fibroblast growth factor
  • FGF-2 fibroblast growth factor-2
  • KGF keratinocyte growth factor
  • 0 members of family of vascular endothelial growth factors in particular, placental growth factor
  • PIGF interleukines
  • IL-6, IL-8 members of family of matrix metalloproteinases
  • MMP-3 metalloprote ⁇ nase-3
  • GCSF granulocyte-colony stimulating 5 factor
  • GM-CSF granulocyte-macrophage colony-stimulating factor
  • PEGF platelet-derived endothelial cell growth factor
  • BB platelet-derived growth factor
  • the negative regulators or anti-angiogenic factors include members of family of inteferons, in particular, interferon alpha, members of family of tissue inhibitors of matrix metalloproteinases (TIMPs), platelet derived growth factor-4 (PDGF-4), transforming growth factor-b (TGFb) RGD-peptides 50 proteolytic fragments of growth hormone, placental lactogen and prolactin
  • TGFb transforming growth factor-b
  • angiogenesis inhibitors originate from intercellular matrix proteins circulating in blood such as fibronectin, plasminogen, collagen, secreted protein acidic and rich in cysteine (SPARC), thrombospond ⁇ n-1 (TSP-1 ), serpine-antithrombine etc
  • Angiogenic factors such as kanstatin and tumstatin are fragments of collagen IV, restin of collagen XV while endostatins are fragments of C-terminal domain of collagen-XVIII
  • angiostatins that are proteolytic fragments of plasminogen
  • angiogenesis regulators are to be found in an intercellalar matrix in a bioactive form
  • the receptors corresponding to these regulators are located on the surface of endothelial cells Under physiological conditions the addition of an angiogenic factor results in a cascade of reactions leading either to activation or inhibition of endothelial cells
  • angiogenic factors are an indispensable part of angiogenesis system and they themselves could be related to angiogenic factors
  • a method and a composition for immunotherapy of inflammatory and autoimmune diseases described in US application No 20060140936A 1 published June 29, 2006
  • Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed
  • the different targets include ( ⁇ ) proinflammatory effectors of the innate immune system, ( ⁇ ) coagulation factors, and (in) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (in) are neither a proinflammatory effector of the immune system nor a coagulation factor
  • the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune- dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the
  • a multispecific antagonist is used in the treatment of diseases caused by inflammatory immune system effectors or by blood coagulation factors
  • diseases include inter alia septicemia or septic shock, an infectious disease, a neuropathy, graft versus host disease or transplant rejection, acute respiratory distress syndrome, a granulomatous disease, asthma, atherosclerosis, cachexia, a pathologic angiogenesis, cancer, a coagulopathy, acne, giant cell arteritis, or myocardial ischemia
  • the above-described immunotherapy method and composition are intended for functional suppression of the target pathological cells with no account to as their specific contribution to a pathogenesis autoimmune mechanism of particular disease Therefore the main disadvantage of the above method and composition is their low efficiency for diseases with angiogenesis disorders related to autoimmune processes
  • This protein conjugate comprises pro-angiogenic factor VEGF and a plant toxin gelonin wherein VEGD is bound to tumour-associated receptor VEGFR expressed on a cell surface of tumour blood vessels and wherein the tumour types to be effected by said conjugate include inter aha squamous cell carcinoma, adenocarcinoma, small-celled carcinoma, glioma or neuroblastoma Any growth factor could be used for its intended application, should it be bound to the tumour-associated endothelial cells and to be more precise, to the growth factor receptors on the surface of the cells in question and with FGF and TGF beta mentioned in this connection, these also being the pro-angiogenic factors It is strongly emphasized that a growth factor receptor should be present in higher concentrations on the surface of the tumour-associated endothelial cells than on any other kind of cells being not tumour- associated The above conjugate was successfully applied for growth suppression of
  • IVIG intravenous immunoglobulin
  • IVIG intravenous immunoglobulin
  • a specially separated and processed immunoglobulin fraction which is made of collected plasma pool from several thousand of donors having a vast distribution of antibodies as to their subclasses and specificity
  • the antibodies in question often include the ones that with high specificity identify the areas on the pathologic autoantibodies or on the receptors of subject's pathologic modified immunocompetent cells Therefore, when administered to the patients with autoimmune diseases, IVIG often results in a pronounced clinical effect
  • IVIG intravenous immunoglobulin
  • the above method includes the stage of determining the angiostatin concentration, wherein said angiostatin is a protein having a sufficient activity to inhibit the proliferation of endothelial cells and a molecular weight from 38 to 45 kD which is according to electrophoresis data in polyacrylamide gel under restoration conditions
  • angiostatin is a protein having a sufficient activity to inhibit the proliferation of endothelial cells and a molecular weight from 38 to 45 kD which is according to electrophoresis data in polyacrylamide gel under restoration conditions
  • a pharmaceutical composition comprising an antibody that is specifically bound to angiostatin
  • the above device does not provide for defining the autoantibodies against angiogenic factors Summary of the Invention
  • the inventors have found out that many kinds of diseases with angiogenesis disorders are accompanied by the appearance and the increase of concentrations of neutralizing antibodies which interact with various angiogenic factors and interfere with their physiologic activity
  • the inventors have disclosed that elimination of autoantibodies against angiogenic factors from a subject's body and neutralization as well as removal or elimination from a subject's body of the immunocompetent cells taking part in the production of neutralizing autoantibodies results in restoration of normal angiogenesis, the elimination of pathologic symptoms and complete cure
  • the inventors have found out that the production of immunological tolerance to angiogenic factors against which at the pre-clinical stage a subject's body starts to produce autoantibodies is an efficient means for prevention and treatment of primary stages of autoimmune diseases related to angiogenesis disorders
  • the use of various methods of producing the immunological tolerance results in a sharp decrease of the content of neutralizing autoantibodies in a subject's body
  • the production of immunological tolerance has a prevention effect, while at the primary stages of the disease it has a treatment effect i e helps to restore normal angiogenesis, to eliminate pathologic symptoms and to completely cure the disease
  • the inventors have discovered a so far unknown phenomenon consisting in the appearance and sharp decrease of the concentration of autoantibodies against angiogenic factors in blood of the patients suffering from diseases with angiogenesis disorders This phenomenon is proposed as the basis of a pathogenesis research in relation to such diseases It is the aim of the present invention to provide methods and means for fighting a vast number of diseases with autoimmune angiogenesis disorders and also to provide a new method and a new test-system of monitoring of angiogenesis disorders in a subject's body as a result of an increased content of autoantibodies against angiogenic factors in said body
  • An immunomodulating portion of said complex could be both an immunostimulator and an immunosuppressor
  • An angiogenic factor of said complex is made so that it interacts with immunocompetent cells belonging to the specific clones of B-lymphocytes and plasma cells that are the derivatives thereof and also with T- lymphocytes
  • An antigenic portion of the above complex could be made in the form of an artificial structure copying or resembling the antigenic determinants of natural angiogenic factors
  • An immunosuppressor of said protein complex presents monoclonal antibodies against surface receptors of immunocompetent cells, or a toxin selected from the group including toxins of bacterial, plant animal, fungal or virus origin, or a medication of cytotoxic action, or a combination of monoclonal antibodies toxins and medications
  • the monoclonal antibodies can be selected from the groups including anti CD3, anti CD4, anti CD19 ant ⁇ CD20, anti CD21 , anti CD22, anti CD23, anti CD40 and anti CD80
  • a toxin of a protein complex immunosuppressor is preferably a bacterial toxin
  • a medication of a protein complex immunosuppressor can be specifically selected from groups related to kalicheamycin, thiotepa, taxan, nitrous ype ⁇ te, ethylene imine derivatives, alkyl sulfonate t ⁇ azene, taxol, kamptotecin, azase ⁇ ne, tamoxifen, dolastine/au ⁇ statine, haemiasterlin and maitanzmod ethoposide, procarbazine, carmustine, phenyl butyrate, br ⁇ ostat ⁇ ne-1 and leucovorin, enzymes, e g , protease, lipase, phosphohpase, RNAse, DNAse, vinca alkaloids, e g , vincristine, vinblastine, antibiotics, e g , actinomycin D, mitomycin C,
  • Methylhydrazine derivatives platinum coordinating compositons, e g , cisplatin,
  • Cortisol derivatives e g , methylprednisolone, prednisone, dexamethasone, nonsteroid antiinflammatory medications, e g , COX-2 inhibitors, salicylates para-aminophenol derivatives, indole and indene derivatives, heteroarylacetic acids, arylpropionic acids, anthranihc acids enolic acids, alkanons, 2,3-d ⁇ phenyltetrahydrofuran, urea derivatives, e g , nitrosourea, folic acid analogues, e g , methotrexate, aminopterin, and also the combinations of substances of several chemical groups, groups of origin and groups according to the mechanism of action
  • An angiogenic factor of a protein complex could be both a pro-angiogenic factor and an anti-angiogenic factor
  • Pro-angiogenic factors of a protein complex are selected from the group including the groups of fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukins, platelet- derived growth factors, angiopoetms, tumor-necrosis factors, matrix metalloproteinases and, in particular from transforming growth factor beta 1 , intercellular adhesion molecule 1 , hepatocyte growth factor, nerve growth factor, connective tissue growth factor, tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor-1 , thymidine-phosphorylase
  • the above aim is achieved due to use of the protein complexes described above for prevention and treatment of diseases with angiogenesis disorders
  • a protein complex could be in the form of an immunoglobulin-like structure, in which fragment of variable domen is identical to fragment of an angiogenic factor, while a constant domen of an immunoglobulin-like structure acts as immunosuppressor
  • the donor immunoglobulins or the ones obtained by cell cultu ⁇ ng actually present multi-functional protein complexes having a structure comprisng at least two domens one of said domen being a variable immunoglobulin domen for the case of donor anti-idiotypic antibodies that reacts with the discovered pathologic autoantibodies against angiogenic factors is actually a structural fragment of said angiogenic factor
  • the second domen of said structure that is an immunoglobulin constant domen when introduced into a subject's body performs a cascade of biological processes leading to the suppression of pathologic autoantibody products by immunocompetent cells i e this essentially being an effector portion of said protein complex Taking into account the availability of the cell cultu ⁇ ng methods for a discrete production of the variable and
  • An anti-angiogenic factor of a protein complex in the above variant could be selected from the group comprising members of families like inteferons, tissue inhibitors of metalloproteinases fibroblast growth factors, endothelial growth factors, vascular endothelial growth factors, plasminogen, collagen fibronectin, prolactin, growth hormone, placental lactogen and thrombospondin and fragments thereof or it could be in the form of an artificial structure copying or resembling the antigen determinants of natural anti-angiogenic factors
  • An effector portion of a protein complex in the above variant presents a toxin selected from the group including the toxins of bacterial, plant, animal, fungal or virus origin, cytotoxic antibiotics, ions of heavy metals in various forms, photosensitazers, radionuclides or the combinations thereof
  • Pro-angiogenic factors in the above variant of a protein complex could be selected from a group including group comprising members of families like fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukins, platelet-derived growth factors, angiopoietins, tumor-necrosis factors, matrix metalloproteinases and, in particular, transforming growth factor beta 1 , intercellular adhesion molecule, hepatocyte growth factor, nerve growth factor, connective tissue growth factor tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor 1 , thymidine- phosphorylase
  • Anti-angeoginic factors in the protein complex of present invention could be selected from the members of families like inteferons, tissue inhibitors of metalloproteinases, fibroblast growth factors placental endothelial growth factors, vascular endothelial growth factors, plasminogens, collagens, fibronectins, prolactins, growth hormones, placental lactogens, thrombospondins and fragments thereof
  • Angiogenic factors in the above variant of a protein complex could be made in the form of an artificial I O structure coping, resembling, presenting the antigenic determinants of natural pro- or anti-angiogenic factors
  • the polymer carriers in the above variant of a protein complex could be selected from the group including polymer particles, both magnetic and non-magnetic ones, continuous and hollow fibers, single-layer or multi-layer membranes
  • Filed is a method for prevention and treatment of diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex comprising an antigen portion and an immunomodulating portion, wherein the above-set aim is 0 achieved due to a) pre-defining the content of an angiogenic factor/factors in the subject's biologic samples and determining the factors which concentration exceed the normal level , b) defining a kind/kinds of angiogenic factors against which the patient's body produces elevated levels of autoantibodies, 5 c) producing a first variant of a protein complex (according to claims from 1 to 13) containing the identified angiogenic factors as an antigenic portion and an immunomodulating portion and d) administration of said protein complex for modulating of an immune response to the angiogenic factor in question
  • Said protein complex is administered intravenously, intraarterial, intramusculary, intraosseously 0 intrafascialy, intralumbaly, hypodermally, intraorganically and also to the surface of mucous membranes e g , intraconjunctival, intranasal, intratracheal, intrabronchial, intraalveolar, intravaginal, intrauteral, per os, per rectum
  • a filed method for prevention and treatment of diseases with angiogenesis disorders is used for the following groups of diseases including cardiovascular diseases, e g , embolism, thrombosis, stroke, infarction arteriosclerosis aneurism, apoplexy, stenocardia, myocardial angiogenesis insufficiency, angiostenosis teleangiectasia, restenosis, 0 respiratory diseases, e g , chronic pneumonia, pulmonary fibrosis, pulmonary emphysema bronchial asthma, urinary tract diseases, e g , glomerulonephritis, cystitis, kidney bladder stone kidney stone gastrointestinal compt diseases, e g , gastritis, duodenitis, pancreatitis, hepatitis, chronic appendicitis, ulcerative colitis, celiac disease, Crohn's disease, intestinal absorption
  • cardiovascular diseases e g , embolism, thrombosis, stroke, infarction arterios
  • connective tissue diseases e g , pathologic proliferation of connective tissue in organs, in particular, pulmonary fibrosis, cystic fibrosis, dermatofibrosis, hepatic fibrosis hepatic cirrhosis, urethrofibrosis, renal fibrosis, cardiac fibrosis, infantile endocardial fibrosis, pancreafibrosis collagenoses, skin diseases, e g , atopic dermatitis, derma cornification disorders leukoplakia, lichen planus psoriasis, wound granulation, hypertrophic scars, scleroderma, pemphigus, cat scratch disease, neoplastic diseases, e g , progression of non-malignant growths, malignant growths under remission and acute conditions, tumour angiogenesis, tumour metastases, transplantation diseases, e g , inconsistent blood transfusion, graft rejection reaction, "graft- versus-host" disease, diseases related to sense organs
  • An angeoginic factor of a protein complex used in the present invention and treatment method is produced so that it interacts with immunocompetent cells belonging to the specific clones of B- lymphocytes and to the plasma cells that are derivatives thereof, and also to T-lymphocytes
  • Another method of treatment diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex containing an antigen portion and an effector portion makes it possible to achieve the above-set aim due to pre-defining a kind/kinds of angiogenic factors against which a subject's body overgenerates autoantibodies producing a protein complex containing an identified angiogenic factor and using said protein complex to completely remove from said subject's body said autoantibodies and/or the cells-producers thereof
  • a protein complex according to this variant of a treatment method is produced so that its effector portion is intended to specifically influence the target cell, while said influence is provided by introducing said complex into a subject's body
  • Said protein complex is injected intravenous, intraarterial, intramascular, intraosseous hypodermic, intraorganic, intrafascial, intralumbar, per os, per rectum
  • a filed method for treatment of diseases with angiogenesis disorders is used for the following groups of diseases including cardiovascular diseases, respiratory diseases, urinary tract diseases, gastrointestinal compt diseases, reproductive pathology, nervous system diseases, mental health disorders, musculoskeletal system diseases, endocrine disorders, connective tissue diseases, skin diseases, diseases related to sense organs neoplastic diseases, transplantation diseases, infectious diseases and the complications thereof
  • a protein complex according to a method of treatment described below is produced so that its effector portion presents a polymer carrier with an antigen immobilized thereon, while its influence is effected by means of bio-specific sorption of a subject's biologic fluid
  • An angiogenic factor according to this variant of a treatment method could be either a pro- or a ⁇ ti- angiogenic factor
  • a treatment method according to the variant in question could be performed either simultaneously or after the sorption process is completed
  • Blood, blood plasma, lymph, cerebrospinal fluid and/or bone marrow could be used as a biologic fluid
  • a third variant of a treatment method for diseases with angiogenesis disorders in animals consisting in effecting the pathologic autoantibodies present in the animal's body or the cell-producers of said autoantibodies by a medication of intravenous immunoglobulin, and further consisting in the selection of intravenous immunoglobulins reacting with the autoantibodies characteristic of a specific disease and the administration of the selected immunoglobulins to the animal makes it possible to achieve the aim set by the invention due to said pathologic autoantibodies being the antibodies against the angiogenic factors while the presence of said pathologic autoantibodies and/or of respective immunocompetent cells is defined directly in a biologic sample of said animal, and the anti-idiotypic antibodies that are used as immunoglobulins are taken from a donor/donors of the same biologic type so that their anti-idiotypic antibodies would most efficiently react with the pathologic autoantibodies and the
  • autoantibodies could be defined by analyzing the interaction of a wide range of antigens immobilized on carries with a sample/samples of the animal's biologic samples with further analysis of the quantity and quality of said antoantibodies having bound to said antigens
  • the antigens immobilized on carriers are mainly related to angiogenic factors
  • a selective concentration of donor anti-idiotypic antibodies could be provided by means of an affinity sorption on the animal's pathologic autoantibodies immobilized on a hard carrier while said immobilization of said pathologic autoantibodies on said hard carrier could be performed by a covalent or non-covalent method either immediately after the sorption on an antigen is completed or after the de- sorption from an antigen
  • a selective concentration of the donor anti-idiotypic antibodies could also be performed by means of separation of immunocompetent cells from the donor biologic samples, generation of hyb ⁇ doma and its further cultivation with separation of the donor anti-idiotypic antibodies
  • the hyb ⁇ doma cultivation is performed either outside the animal's body or actually therein
  • a selective concentration of the donor anti-idiotypic antibodies could also be performed by means of genetic engineering and introducing the genetic structure into the animal's cells
  • the efficiency of binding the donor immunoglobulins with the pathologic autoantibodies or receptors on the surface of immunocompetent cells is improved by their chemical modification which is preferably provided either by means of binding the additional chemical groups to an antigen molecule or by binding the antibodies to a bio-compatible soluble polymer or by removing a portion of an antibody molecule
  • the decrease of the content of pathologic autoantibodies in the subject's blood or cerebrospinal fluid is performed by means of an immunosuppressive therapy or by means of selective sorption of autoantibodies from blood or from cerebrospinal fluid
  • animals there is meant fish, amphibias, reptiles, birds and mammals
  • angiogenic factors with a normal or modified due to pathology structure are selected from the group family members like plasminogen and its fragments, e g , angiostatin, collagen-XVIII and its fragments, e g , endostatin, a group of fibroblast growth factors (FGF), placental growth factor of endothelial cells and vascular growth factor of endothelial cells (vascular permeability factor), fibronectin, prolactin, 5 thrombospondin-l and fragment
  • a biologic preparation could be selected from the group including tissue samplings, blood and its constituents, lymph, cerebrospinal fluid, urea, saliva, lacrimal fluid
  • test-system to investigate the origins of pathologic angiogenesis in a subject's body was designed, said system comprising at least one carrier for immobilzation of one or a number of antigens, a biologic preparation and an element for defining the presence of autoantibodies against said antigens in said preparation, wherein the angiogenic factors are used as antigens
  • test-system element for defining the presence in said preparation of autoantibodies against said antigens is preferably made in the form of revealing reagents or in the form of a direct detection device
  • Fig 1 illustrates an implementation example of a test system in the form of a flexible immune kit (Titertek) 5 with one well of said kit shown as an example Molecules 1 of antigen i e angiogenic factor immobilized on a well 2 of said kit are shown virtually Molecules of just one angiogenic factor could be immobilized throughout the whole of the kit or of various angiogenic factors in the groups of neighboring wells, or of one factor per well
  • Fig 2 illustrates an implementation example of a test-system in the form of a set of carrier particles 5
  • Molecules 1 of an antigen i e angiogenic factor immobilized on particles 5 are shown virtually Molecules of just one angiogenic factor could be immobilized on all particles or of various angiogenic factors on different particles or of several kinds of angiogenic factors on just one particle
  • Molecules 3 of 5 autoantibodies contained in a biologic preparation are also shown virtually
  • Numeral 6 designates antibodies that are non-sorbing on a specific antigen
  • Numerals 7 and 8 designate respectively a tip and a magnetic rod of a magnetic manipulator A reaction is performed in a laboratory vessel 9
  • Angiostatin (Sigma) (50mg) dissolved in 10 ml of 0,1 M sodium phosphate buffer was mixed with 0 1 ml of 2%gelon ⁇ n and then added to the mixture of 0,5 ml of 2% activated copolymer of polyvinyl pyrrolidone and acrolein A conjugation reaction was performed at a room temperature with constant stirring for 2 hrs Separation of low-molecular products was made by dialysis against 0,9% solution of NaCI A protein complex thus produced was used for intravenous injection as a component of a pharmaceutical composition
  • a solution of a complex produced as described in Example 2 was added with up to 10% of a glucose solution, up to 500 units of heparin and further sterilized by filtration through disposable membrane filters Amicon A sterile solution in sealed bottles was stored at +4 0 C for maximum 5 days until the actual use
  • the above protein complex could be used in the treatment of diseases with angiogenesis disorders according to claims from 44 to 47
  • a protein complex thus produced was used for implementing one of the embodiments of the invention filed according to claims from 27 to 43, wherein should an increased content of neutralizing autoantibodies against some angiogenic factor or a group of factors be discovered in a subject's body, a protein complex is prepared and applied, said protein complex comprising the above factor (factors) and means causing the production of immunological tolerance against the above factor (factors) with an immunosuppressive agent used as an immunomodulating portion
  • an immunosuppressive agent used as an immunomodulating portion
  • the production of immunological tolerance as a means of suppressing an autoimmune process is
  • Immunological tolerance could be achieved either by eliminating the specific clones or by introducing the latter into the state of anergy and not only at the early stages of ontogeny
  • the tolerance depends on the appearance of new kinds of activated lymphocytes and it does not depend on the elimination of the old active ones
  • a protein complex is prepared and applied said protein complex comprising the above factors and means causing the production of neutralizing autoantibodies wherein an immunostimulating agent is used as an immunomodulating portion
  • an immunostimulating agent is used as an immunomodulating portion
  • the analysis consists in defining the inhibiting influence of the donor anti-idyotypic antibodies on the interaction of the animal's pathologic autoantibodies with angiogenic factors
  • the choice of a donor/donors is performed on the basis of maximum inhibition by the donor anti-idyotypic antibodies of binding and interaction of the autoantibodies with an antigen
  • the angiogenic factors according to this
  • 15 variant of a treatment method could be either pro- or anti-angiogenic factors
  • This process could be performed in three different ways
  • the concentration of ant ⁇ - ⁇ dyotyp ⁇ c antibodies is provided by means of preparative affinity sorption on mammal pathologic autoantibodies immobilized on a carrier 0
  • the immobilization of pathologic autoantibodies is performed on angiogenic factor already immobilized on a carrier
  • Immobilization of both angiogenic factor and pathologic autoantibodies is performed either by covalent or y non-covalent binding method, however, the combination of the above methods is possible
  • Synthetic ligands could be immobilized on an affinity column instead of autoantibodies with anti-idyotypic antibodies exhibiting an enhanced binding activity in relation to said ligands
  • the substances included into 5 the following groups could be used as such ligands chemical dyes, in particular, dinitrophenol, procion blue and derivatives thereof amino acids, in particular, lysine, arginine, aspartic acid, tyrosine, phenylalanine tryptophan cysteine in D- and L-forms, in the form
  • lectins in particular, lectins from Phaseolus vulgaris, Canavalia ensiformis, ⁇ cin, ab ⁇ n phytohemagglutinin, , clearance lectins,
  • nucleic acids in particular, aptamers and derivatives thereof, oligo or polysaccharides, in particular, heparin, heparan sulpfate dermatan sulphate 5 hyaluronic acid, chitin and derivatives thereof, lipids, in particular, phospholipids and derivatives thereof
  • a number of ligands to be used for concentration of anti-idyotypic antibodies is not limited by those listed above
  • a selective concentration of anti-idyotypic antibodies could also be performed by means of separating 0 immunocompetent cells producing said anti-idyotypic antibodies from the donors' biologic samples generating a hybridoma and cultivating said hyb ⁇ doma with further separation of anti-idyotypic antibodies
  • the cultivation of hybridoma is performed actually inside the animal s body In other cases the cultivation of hybridoma is performed outside the animal s body The cultivation is performed either in the body of an experimental animal or in a cell cultivation reactor
  • Anti-idyotypic antibodies could be subjected to chemical modification after their separation with the aim of improving the efficiency of binding with pathologic autoantibodies or receptors on the surface of immunocompetent cells Said modification could be performed as follows binding the additional chemical groups to an antigen molecule, binding the antibodies to a biocompatible soluble polymer, removing a potion of an antigen molecule
  • the chemical groups bound thereto could belong to various classes, in particular, acyl, ether sulphohydryl, hydroxy/, sulphate, sulphite, carbohydrate, peptide, nucleotide
  • the combinations of chemical groups bound thereto are possible
  • a number of chemical groups bound thereto to increase the efficiency of binding to pathologic autoantibodies or receptors on the surface of immunocompetent cells is not limited by those listed above
  • Bio-compatible soluble polymers to which antibodies would be bound to could belong to various chemical groups, in particular, starch, inulin, hyaluronic acid, chitin, polylactate, polyglycolate, polyvinyl pyrrolidone copolymer of polyvinyl pyrrolidone and acrolein, polyethylene glycol, polyvinyl alcohol, dextran, and modifications thereof
  • binding of anti-idyotypic antibodies to polymers could be both covalent and non-covalent one
  • a number of bio-compatible soluble polymers to which the anti-idyotypic antibodies would be bound to increase the efficiency of binding to pathologic autoantibodies or receptors on the surface of immunocompetent cells is not limited by those listed above
  • anti-idyotypic antibodies is provided on the background of decreasing the content of pathologic autoantibodies in subject's blood or cerebrospinal fluid
  • the decrease of the content of pathologic autoantibodies is provided either by means of an immunosuppressive therapy or by means of selective sorption of autoantibodies from blood or cerebrospinal fluid
  • a method filed provides for a specific treatment of diseases with angiogenesis disorders
  • the indications for application of specific anti-idyotypic antibodies are extending, and, moreover, the specific anti-idyotypic antibodies thus produced are characterized by increased efficiency and improved tolerance on the part of the patient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment

Description

Protein Complexes for Prevention and Treatment of Diseases with Angiogenesis Disorders
Field of the Invention
5 The invention is related to the medical field, and in particular, to protein complexes and the application thereof for the correction of autoimmune processes in human or animal bodies and also to a biochemical research for discovering the biochemical mechanisms of progressing diseases with angiogenesis disorders
Prior Art
I O For better understanding of the particular elements of the invention further there is given the description of biological mechanisms accompanying angiogenesis Angiogenesis is a process of formation of new vessels that is inherent to various activities of normal human or animal bodies (Folkman, J , Cancer Research, 46 467473 (1986) Angiogenesis is most strongly characteristic of such processes as reproduction, embryogenesis and wound healing Although the molecular mechanisms of angiogenesis
15 have not been studied in full, its general principles consist in stimulation and inhibition of the activity of endothelial cells Under normal conditions these cells could be inactive for continuous periods of time from several weeks to a number of decades However, should the necessity arise (as for example in wound healing), the same cells become a subject to fast reproduction and are grown into capillaries within 5 days 0 Although angiogenesis is a highly monitored process under normal conditions, many so-called angiogenic diseases are progressing as a result of chronic angiogenesis disorders
Various angiogenesis regulators have been discovered, both positive and negative ones The division into positive and negative ones turns out to be sufficiently conditional, since one and the same factor under various experimental conditions could have quite a different influence that is often related to proteolytic 5 cleavage or to modification of an original molecule when new structures having a reverse physiological direction are formed
The positive regulators or pro-angiogenic factors include as follows members of family of fibroblast growth factors (FGF), in particular, basic fibroblast growth factor (bFGF), fibroblast growth factor-2 (FGF-2) and keratinocyte growth factor (KGF), 0 members of family of vascular endothelial growth factors, in particular, placental growth factor
(PIGF) and vascular endothelial growth factor A (VEGF-A), members of family of interleukines, in particular, ιnterleukιnes-6 and 8 (IL-6, IL-8), members of family of matrix metalloproteinases, in particular, metalloproteιnase-3 (MMP-3) members of family of colony stimulating factors, in particular, granulocyte-colony stimulating 5 factor (GCSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), members of family of platelet-derived growth factors, in particular, platelet-derived endothelial cell growth factor (PDEGF) and platelet-derived growth factor-BB, members of family of angiopoietins, in particular, angιopoιetιn-1 and -2 (Ang 1 , 2) members of family of insulin-like growth factors, in particular, insulin-like growth factor 1 (IGF-1 ), 0 members of family of tumor-necrosis factors, in particular, tumor-necrosis factor-alpha (TNF- alpha), intercellular adhesion molecule factor (ICAM-1 ), nerve growth factor (NGF) .transforming growth factor beta 1 (TGF-beta 1 ), hepatocyte growth factor (HGF), connective tissue growth factor (CTGF) tenascin-R (TN-R), prolactin, growth hormone, placental lactogen, angiogenine, thymidine phosphorylase 5 (TP) etc
The negative regulators or anti-angiogenic factors include members of family of inteferons, in particular, interferon alpha, members of family of tissue inhibitors of matrix metalloproteinases (TIMPs), platelet derived growth factor-4 (PDGF-4), transforming growth factor-b (TGFb) RGD-peptides 50 proteolytic fragments of growth hormone, placental lactogen and prolactin Many angiogenesis inhibitors originate from intercellular matrix proteins circulating in blood such as fibronectin, plasminogen, collagen, secreted protein acidic and rich in cysteine (SPARC), thrombospondιn-1 (TSP-1 ), serpine-antithrombine etc
Angiogenic factors such as kanstatin and tumstatin are fragments of collagen IV, restin of collagen XV while endostatins are fragments of C-terminal domain of collagen-XVIII
With account to angiogenic factors the most studied ones are angiostatins that are proteolytic fragments of plasminogen
Most angiogenesis regulators are to be found in an intercellalar matrix in a bioactive form The receptors corresponding to these regulators are located on the surface of endothelial cells Under physiological conditions the addition of an angiogenic factor results in a cascade of reactions leading either to activation or inhibition of endothelial cells
Actually the receptors of angiogenic factors are an indispensable part of angiogenesis system and they themselves could be related to angiogenic factors
Should the components interfering with the activity of angiogenic factors appear at the site of a physiological process, they will cause the disturbance of normal angiogenesis proceeding and will result in a new angiogenesis mediated pathology The inventors have discovered that such interfering components are pathologic autoantibodies against various angiogenic factors These autoantibodies under pathologic conditions in a subject's body start to be produced in the increased quantities causing a number of physiologic disorders that are a basic pathogenesis mechanism The most unexpected was the discovery of elevated concentrations of autoantibodies to various angiogenic factors on the early stages of neoplasic diseases in blood and tissues of experimental animals and cancer patients, suggesting the autoimmune origin of malignant growth
At the same time it is quite often when particular angiogenic factors are produced in increased quantities thus also causing pathologic disorders In this case the stimulation of the production of autoantibodies against these angiogenic factors could also decrease the intensity of pathologic disorders and would have a curing effect
Therefore it is necessary to correct the disorders of angogenesis processes by influencing the activity of various angiogenic factors with the help of monitoring autoimmune processes This correction could be performed both by means of decreasing the content of pathologic autoantibodies in a subject's body or by inhibiting their production in the immunocompetent cells and by means of decreasing the activity of angiogenic factors by stimulating the production of autoantibodies used for their neutralization
Known are different methods of effecting angiogenesis processes with the aim of prevention and treatment of a number of diseases Known is a method and a composition for immunotherapy of inflammatory and autoimmune diseases described in US application No 20060140936A 1 published June 29, 2006 Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed The different targets include (ι) proinflammatory effectors of the innate immune system, (ιι) coagulation factors, and (in) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (in) are neither a proinflammatory effector of the immune system nor a coagulation factor When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune- dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve proinflammatory effectors of the innate immune system or coagulation factors Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis According to this method it is proposed to use a multispecific antagonist that reacts specifically with at least two different targets The targets are selected from the group consisting of (A) proinflammatory effectors of the innate immune system, (B) coagulation factors, (C) complement factors and complement regulatory proteins, and (D) targets specifically associated with an inflammatory or immune-dysregulatory disorder or with a pathologic angiogenesis or cancer, wherein the latter target is not (A)1 (B) or (C) When the multispecific antagonist comprises a single multispecific antibody, then CD74 is excluded as a target of the antagonist Furthermore, when the multispecific antagonist comprises a combination of separate antibodies, combinations are excluded where one of the antibodies targets a B-cell antigen and the other antibody targets a T-cell, plasma cell, macrophage or inflammatory cytokine Combinations of separate antibodies are also excluded where one of the antibodies targets CD20 and the other antibody targets C3b or CD40
A multispecific antagonist is used in the treatment of diseases caused by inflammatory immune system effectors or by blood coagulation factors These diseases include inter alia septicemia or septic shock, an infectious disease, a neuropathy, graft versus host disease or transplant rejection, acute respiratory distress syndrome, a granulomatous disease, asthma, atherosclerosis, cachexia, a pathologic angiogenesis, cancer, a coagulopathy, acne, giant cell arteritis, or myocardial ischemia However, the above-described immunotherapy method and composition are intended for functional suppression of the target pathological cells with no account to as their specific contribution to a pathogenesis autoimmune mechanism of particular disease Therefore the main disadvantage of the above method and composition is their low efficiency for diseases with angiogenesis disorders related to autoimmune processes
Known is a method disclosed in US patent 6,863,896 published March 8 2005 which consists of producing an immune response in a mammal, comprising the step of administering mucosally to a mammal an admixture comprising an immunogen and a plant lectin, whereby the mammal produces an immune response to the immunogen which is greater relative to the immune response to the immunogen produced in the absence of the plant lectin However, the above composition and a method of application thereof also do not provide for the correction of the states related to angiogenesis disorders
Known is a protein conjugate and also a method of application thereof described in US patent No 6,451 ,312 This protein conjugate comprises pro-angiogenic factor VEGF and a plant toxin gelonin wherein VEGD is bound to tumour-associated receptor VEGFR expressed on a cell surface of tumour blood vessels and wherein the tumour types to be effected by said conjugate include inter aha squamous cell carcinoma, adenocarcinoma, small-celled carcinoma, glioma or neuroblastoma Any growth factor could be used for its intended application, should it be bound to the tumour-associated endothelial cells and to be more precise, to the growth factor receptors on the surface of the cells in question and with FGF and TGF beta mentioned in this connection, these also being the pro-angiogenic factors It is strongly emphasized that a growth factor receptor should be present in higher concentrations on the surface of the tumour-associated endothelial cells than on any other kind of cells being not tumour- associated The above conjugate was successfully applied for growth suppression of a mouse experimental tumour However, the conjugate in question was used for the purposeful elimination of endothelial cells of tumour microvessels, which is not directly related to autoimmune processes And it is the autoimmune mechanisms that form the pathogenesis basis of spontaneous tumours and of many other angiogenic diseases in human and mammal bodies
Therefore the main disadvantage of above conjugate and a method of application thereof is their low efficiency for diseases with angiogenesis disorders caused by autoimmune processes
Also known is an antigen conjugate and artificial carriers in the treatment of autoimmune diseases by means of biospecific sorption of autoantibodies and immunocompetent cells described in Russian patent No 2167705, published May 27, 2001
However, said conjugate and said method of application thereof do not make it possible to efficiently correct the states related to angiogenesis autoimmune disorders
Known is an application of intravenous immunoglobulin (IVIG) to treat the states of immunity disorders IVIG presents a specially separated and processed immunoglobulin fraction which is made of collected plasma pool from several thousand of donors having a vast distribution of antibodies as to their subclasses and specificity The antibodies in question often include the ones that with high specificity identify the areas on the pathologic autoantibodies or on the receptors of subject's pathologic modified immunocompetent cells Therefore, when administered to the patients with autoimmune diseases, IVIG often results in a pronounced clinical effect
Officially acknowledged is the use of IVIG in the treatment of thrombocytopenic purpura Kawasaki disease, allogenic transplantation of haemopoietic cells, retinochoroiditis of Birdshot Besides, it is strongly recommended by those keen in the art to use IVIG for some kinds of cytopenia and haemophilia with inhibitory autoantibodies to factor VIII There are also some promising results in the treatment of a number of neurologic disorders like Guillain-Barre syndrom, inflammatory demielinating polyneuropathy, dermatomyositis, myastenia gravis and multiple sclerosis To explain the mechanism of IVIG versatility a number of hypotheses were proposed like disabling the FC-receptors on the surface of phagocytes, monocytes, neutrophils and eosinophils, neutralization of circulating pathologic autoantibodies by antiidiotype antibodies, inhibition of negative processes related to complement activation, - modulation of cytokine network, and selection of immune repertoire by means of interaction with T- and B-lymphocytes
Known is a therapeutic methods for inhibiting tumor metastasis and for treating primary tumors (US patent 5965130, published October 12, 1999) administering to a mammal a preparation of intravenous immunoglobulin (IVIG) However, this method does not consider the specific features of the subject's pathologic process and the inhibiting characteristics of the anti-idiotypic antibodies in the donor IVIG This substantially decreases the therapeutic efficiency of IVIG application for neoplastic diseases
Known is a method for preparing Ig fractions from human polyvalent intravenous Immunoglobulins and its application in the treatment of autoimmune diseases (US patent 6,932,969, published August 23 2005) The method consists in separating a fraction of antibodies which react in an anti-idiotypic way with pathologic autoantibodies against actin, myosin, basic myelin protein and tubulin However the above method does not consider the fact of formation of pathologic autoantibodies against angiogenic factors and therefore it cannot be efficiently applied in the treatment of diseases with angiogenesis disorders
Known are a number of methods to diagnose diseases based on identification of autoantibodies that are specific to particular autoantigens Known is a method of diagnosing or predicting diseases related to angiogenesis such as cancer, arthritis, macular degeneration and diabetic retinopathy (Russian patent application No 96122485 published May 10, 1999)
The above method includes the stage of determining the angiostatin concentration, wherein said angiostatin is a protein having a sufficient activity to inhibit the proliferation of endothelial cells and a molecular weight from 38 to 45 kD which is according to electrophoresis data in polyacrylamide gel under restoration conditions In the above application there is also mentioned a pharmaceutical composition comprising an antibody that is specifically bound to angiostatin
The disadvantage of the above method is its insufficient specificity as to the diagnosis of malignant growths Russian patent application No 2005101643, published June 27, 2005 discloses a device containing at least one carrier for immobilizing one or a number of antigens, a biologic preparation and an element for defining the presence of autoantibodies against said antigens in said preparation
However, the above device does not provide for defining the autoantibodies against angiogenic factors Summary of the Invention The inventors have found out that many kinds of diseases with angiogenesis disorders are accompanied by the appearance and the increase of concentrations of neutralizing antibodies which interact with various angiogenic factors and interfere with their physiologic activity
The inventors have disclosed that elimination of autoantibodies against angiogenic factors from a subject's body and neutralization as well as removal or elimination from a subject's body of the immunocompetent cells taking part in the production of neutralizing autoantibodies results in restoration of normal angiogenesis, the elimination of pathologic symptoms and complete cure
The inventors have found out that the production of immunological tolerance to angiogenic factors against which at the pre-clinical stage a subject's body starts to produce autoantibodies is an efficient means for prevention and treatment of primary stages of autoimmune diseases related to angiogenesis disorders The use of various methods of producing the immunological tolerance results in a sharp decrease of the content of neutralizing autoantibodies in a subject's body At the pre-clinical stages of disease the production of immunological tolerance has a prevention effect, while at the primary stages of the disease it has a treatment effect i e helps to restore normal angiogenesis, to eliminate pathologic symptoms and to completely cure the disease
The inventors have discovered a so far unknown phenomenon consisting in the appearance and sharp decrease of the concentration of autoantibodies against angiogenic factors in blood of the patients suffering from diseases with angiogenesis disorders This phenomenon is proposed as the basis of a pathogenesis research in relation to such diseases It is the aim of the present invention to provide methods and means for fighting a vast number of diseases with autoimmune angiogenesis disorders and also to provide a new method and a new test-system of monitoring of angiogenesis disorders in a subject's body as a result of an increased content of autoantibodies against angiogenic factors in said body
A protein complex comprising an antigen and an attached thereto effector portion with immunomodulating activity makes it possible to achieve the above aim due to said antigen presenting an angiogenic factor
An immunomodulating portion of said complex could be both an immunostimulator and an immunosuppressor
An angiogenic factor of said complex is made so that it interacts with immunocompetent cells belonging to the specific clones of B-lymphocytes and plasma cells that are the derivatives thereof and also with T- lymphocytes
An antigenic portion of the above complex could be made in the form of an artificial structure copying or resembling the antigenic determinants of natural angiogenic factors
An immunosuppressor of said protein complex presents monoclonal antibodies against surface receptors of immunocompetent cells, or a toxin selected from the group including toxins of bacterial, plant animal, fungal or virus origin, or a medication of cytotoxic action, or a combination of monoclonal antibodies toxins and medications
The monoclonal antibodies can be selected from the groups including anti CD3, anti CD4, anti CD19 antιCD20, anti CD21 , anti CD22, anti CD23, anti CD40 and anti CD80
A toxin of a protein complex immunosuppressor is preferably a bacterial toxin A medication of a protein complex immunosuppressor can be specifically selected from groups related to kalicheamycin, thiotepa, taxan, nitrous ypeπte, ethylene imine derivatives, alkyl sulfonate tπazene, taxol, kamptotecin, azaseπne, tamoxifen, dolastine/auπstatine, haemiasterlin and maitanzmod ethoposide, procarbazine, carmustine, phenyl butyrate, brιostatιne-1 and leucovorin, enzymes, e g , protease, lipase, phosphohpase, RNAse, DNAse, vinca alkaloids, e g , vincristine, vinblastine, antibiotics, e g , actinomycin D, mitomycin C, pyramycin, chloramphenicol, cyclosporin, tacrolymus, micophenolate, motephyl, bleomycin, a group of dien antibiotics, e g , dinemycin A, esperamycin, a group of anthracyclines, e g , daunorubicin, doxorubicin, idarubicin epirubicin, 2- pirrolinodoxorubicin, morpholinodoxorubicin and cyanomorpholinodoxorubicin, a group of anthramycins, e g , porothramycin B and pιrrolo-[2, 1 -c][1 ,4]benzodιazepιne4 purine analogues, e g , azathiopnne, mercaptopuπne, chlorambucil, pyπmidine analogues, e g , cytozine arabinozide, immunusuppressor analogues, e g , azathiopnne, cyclospoπne, penicilamine, antimalarial medications, e g , chloroquine, hydroxychloroquine, antimetabolites, e g , methotrexate, alkylating agents, e g , cyclophosphamide,
Methylhydrazine derivatives, platinum coordinating compositons, e g , cisplatin,
Cortisol derivatives, e g , methylprednisolone, prednisone, dexamethasone, nonsteroid antiinflammatory medications, e g , COX-2 inhibitors, salicylates para-aminophenol derivatives, indole and indene derivatives, heteroarylacetic acids, arylpropionic acids, anthranihc acids enolic acids, alkanons, 2,3-dιphenyltetrahydrofuran, urea derivatives, e g , nitrosourea, folic acid analogues, e g , methotrexate, aminopterin, and also the combinations of substances of several chemical groups, groups of origin and groups according to the mechanism of action
An angiogenic factor of a protein complex could be both a pro-angiogenic factor and an anti-angiogenic factor
Pro-angiogenic factors of a protein complex are selected from the group including the groups of fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukins, platelet- derived growth factors, angiopoetms, tumor-necrosis factors, matrix metalloproteinases and, in particular from transforming growth factor beta 1 , intercellular adhesion molecule 1 , hepatocyte growth factor, nerve growth factor, connective tissue growth factor, tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor-1 , thymidine-phosphorylase The above aim is achieved due to use of the protein complexes described above for prevention and treatment of diseases with angiogenesis disorders
A protein complex could be in the form of an immunoglobulin-like structure, in which fragment of variable domen is identical to fragment of an angiogenic factor, while a constant domen of an immunoglobulin-like structure acts as immunosuppressor The donor immunoglobulins or the ones obtained by cell cultuπng actually present multi-functional protein complexes having a structure comprisng at least two domens one of said domen being a variable immunoglobulin domen for the case of donor anti-idiotypic antibodies that reacts with the discovered pathologic autoantibodies against angiogenic factors is actually a structural fragment of said angiogenic factor The second domen of said structure that is an immunoglobulin constant domen when introduced into a subject's body performs a cascade of biological processes leading to the suppression of pathologic autoantibody products by immunocompetent cells i e this essentially being an effector portion of said protein complex Taking into account the availability of the cell cultuπng methods for a discrete production of the variable and constant domens of immunoglobulins with their subsequent combining into a common protein complex the anti-idiotypic antibodies could be related to the protein complexes filed according to the present invention description A second variant of a protein complex comprising an antigen and an effector portion bound thereto to provide the specific influence on a target cell makes it possible to achieve the above aim due to said antigen presenting an angiogenic factor
An anti-angiogenic factor of a protein complex in the above variant could be selected from the group comprising members of families like inteferons, tissue inhibitors of metalloproteinases fibroblast growth factors, endothelial growth factors, vascular endothelial growth factors, plasminogen, collagen fibronectin, prolactin, growth hormone, placental lactogen and thrombospondin and fragments thereof or it could be in the form of an artificial structure copying or resembling the antigen determinants of natural anti-angiogenic factors
An effector portion of a protein complex in the above variant presents a toxin selected from the group including the toxins of bacterial, plant, animal, fungal or virus origin, cytotoxic antibiotics, ions of heavy metals in various forms, photosensitazers, radionuclides or the combinations thereof
A third variant of a protein complex comprising an antigen immobilized on an effector portion in the form of a polymer carrier makes it possible to achieve the above aim due to said antigen comprising an angiogenic factor An angiogenic factor according to this variant could be either a pro- or anti-angiogenic factor
Pro-angiogenic factors in the above variant of a protein complex could be selected from a group including group comprising members of families like fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukins, platelet-derived growth factors, angiopoietins, tumor-necrosis factors, matrix metalloproteinases and, in particular, transforming growth factor beta 1 , intercellular adhesion molecule, hepatocyte growth factor, nerve growth factor, connective tissue growth factor tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor 1 , thymidine- phosphorylase
5 Anti-angeoginic factors in the protein complex of present invention could be selected from the members of families like inteferons, tissue inhibitors of metalloproteinases, fibroblast growth factors placental endothelial growth factors, vascular endothelial growth factors, plasminogens, collagens, fibronectins, prolactins, growth hormones, placental lactogens, thrombospondins and fragments thereof
Angiogenic factors in the above variant of a protein complex could be made in the form of an artificial I O structure coping, resembling, presenting the antigenic determinants of natural pro- or anti-angiogenic factors
The polymer carriers in the above variant of a protein complex could be selected from the group including polymer particles, both magnetic and non-magnetic ones, continuous and hollow fibers, single-layer or multi-layer membranes
15 The above aim is achieved due to use of the second and the third variants of protein complexes in the treatment of diseases with angiogenesis disorders
Filed is a method for prevention and treatment of diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex comprising an antigen portion and an immunomodulating portion, wherein the above-set aim is 0 achieved due to a) pre-defining the content of an angiogenic factor/factors in the subject's biologic samples and determining the factors which concentration exceed the normal level , b) defining a kind/kinds of angiogenic factors against which the patient's body produces elevated levels of autoantibodies, 5 c) producing a first variant of a protein complex (according to claims from 1 to 13) containing the identified angiogenic factors as an antigenic portion and an immunomodulating portion and d) administration of said protein complex for modulating of an immune response to the angiogenic factor in question
Said protein complex is administered intravenously, intraarterial, intramusculary, intraosseously 0 intrafascialy, intralumbaly, hypodermally, intraorganically and also to the surface of mucous membranes e g , intraconjunctival, intranasal, intratracheal, intrabronchial, intraalveolar, intravaginal, intrauteral, per os, per rectum
The administration of said protein complex is performed regularly with the periodicity from 1 to 48 hours, preferably with the periodicity of 24 hours 5 A filed method for prevention and treatment of diseases with angiogenesis disorders is used for the following groups of diseases including cardiovascular diseases, e g , embolism, thrombosis, stroke, infarction arteriosclerosis aneurism, apoplexy, stenocardia, myocardial angiogenesis insufficiency, angiostenosis teleangiectasia, restenosis, 0 respiratory diseases, e g , chronic pneumonia, pulmonary fibrosis, pulmonary emphysema bronchial asthma, urinary tract diseases, e g , glomerulonephritis, cystitis, kidney bladder stone kidney stone gastrointestinal truct diseases, e g , gastritis, duodenitis, pancreatitis, hepatitis, chronic appendicitis, ulcerative colitis, celiac disease, Crohn's disease, intestinal absorption 5 reproductive pathology, e g , endometriosis, frequent fetal loss, abnormal placentation preeclampsia, intrauterine growth contraction, nervous system diseases, e g , multiple sclerosis, chronic fatigue syndrome, encephalitis, myasthenia gravis, mental health disorders, e g , Alzheimer's disease, schizophrenia, mania and depression 0 psychosis, musculoskeletal system diseases, e g , osteoporosis, osteochondrosis, Paget's disease rheumatoid arthritis, osteoarthritis, osteoarthrosis, endocrine disorders, e g , hyperparathyroidism, Grave's disease, Hashimoto's disease, Addison's disease, Cushing's syndrome, diabetes mellitus,
55 connective tissue diseases, e g , pathologic proliferation of connective tissue in organs, in particular, pulmonary fibrosis, cystic fibrosis, dermatofibrosis, hepatic fibrosis hepatic cirrhosis, urethrofibrosis, renal fibrosis, cardiac fibrosis, infantile endocardial fibrosis, pancreafibrosis collagenoses, skin diseases, e g , atopic dermatitis, derma cornification disorders leukoplakia, lichen planus psoriasis, wound granulation, hypertrophic scars, scleroderma, pemphigus, cat scratch disease, neoplastic diseases, e g , progression of non-malignant growths, malignant growths under remission and acute conditions, tumour angiogenesis, tumour metastases, transplantation diseases, e g , inconsistent blood transfusion, graft rejection reaction, "graft- versus-host" disease, diseases related to sense organs, e g , diabetic retinopathy, macular degeneration, myopia, corneal transplantation, rubeothic glaucoma,, infectious diseases, e g , virus, bacterial, fungal infections and the complications thereof
An angeoginic factor of a protein complex used in the present invention and treatment method is produced so that it interacts with immunocompetent cells belonging to the specific clones of B- lymphocytes and to the plasma cells that are derivatives thereof, and also to T-lymphocytes
Another method of treatment diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex containing an antigen portion and an effector portion makes it possible to achieve the above-set aim due to pre-defining a kind/kinds of angiogenic factors against which a subject's body overgenerates autoantibodies producing a protein complex containing an identified angiogenic factor and using said protein complex to completely remove from said subject's body said autoantibodies and/or the cells-producers thereof A protein complex according to this variant of a treatment method is produced so that its effector portion is intended to specifically influence the target cell, while said influence is provided by introducing said complex into a subject's body
Said protein complex is injected intravenous, intraarterial, intramascular, intraosseous hypodermic, intraorganic, intrafascial, intralumbar, per os, per rectum A filed method for treatment of diseases with angiogenesis disorders is used for the following groups of diseases including cardiovascular diseases, respiratory diseases, urinary tract diseases, gastrointestinal truct diseases, reproductive pathology, nervous system diseases, mental health disorders, musculoskeletal system diseases, endocrine disorders, connective tissue diseases, skin diseases, diseases related to sense organs neoplastic diseases, transplantation diseases, infectious diseases and the complications thereof
A protein complex according to a method of treatment described below is produced so that its effector portion presents a polymer carrier with an antigen immobilized thereon, while its influence is effected by means of bio-specific sorption of a subject's biologic fluid An angiogenic factor according to this variant of a treatment method could be either a pro- or aπti- angiogenic factor
A treatment method according to the variant in question could be performed either simultaneously or after the sorption process is completed
Blood, blood plasma, lymph, cerebrospinal fluid and/or bone marrow could be used as a biologic fluid A third variant of a treatment method for diseases with angiogenesis disorders in animals consisting in effecting the pathologic autoantibodies present in the animal's body or the cell-producers of said autoantibodies by a medication of intravenous immunoglobulin, and further consisting in the selection of intravenous immunoglobulins reacting with the autoantibodies characteristic of a specific disease and the administration of the selected immunoglobulins to the animal makes it possible to achieve the aim set by the invention due to said pathologic autoantibodies being the antibodies against the angiogenic factors while the presence of said pathologic autoantibodies and/or of respective immunocompetent cells is defined directly in a biologic sample of said animal, and the anti-idiotypic antibodies that are used as immunoglobulins are taken from a donor/donors of the same biologic type so that their anti-idiotypic antibodies would most efficiently react with the pathologic autoantibodies and the donor anti-idiotypic antibodies received from said donor/donors are selectively concentrated
The presence of autoantibodies could be defined by analyzing the interaction of a wide range of antigens immobilized on carries with a sample/samples of the animal's biologic samples with further analysis of the quantity and quality of said antoantibodies having bound to said antigens
The antigens immobilized on carriers are mainly related to angiogenic factors
The structures that are immunoidentical to antigens could be used as antigens immobilized on hard carriers
Blood samples and its constituent parts, cerebrospinal fluid, saliva, phlegm mucus could be used as the animal's biologic samples
The analysis of the quantity and quality of autoantibodiesis performed by the following methods enzyme- linked immunosorbent assay (ELISA), radioimmunoassay (RIA) immunofluorescence assay electrophoresis, chromatography, mass spectrometry, light microscopy atomic-force microscopy plasmon resonance or the combinations thereof The choice of a donor/donors is performed on the basis of maximum inhibition by the donor anti-idiotypic antibodies of binding and interaction of the autoantibodies with the antigen
A selective concentration of donor anti-idiotypic antibodies could be provided by means of an affinity sorption on the animal's pathologic autoantibodies immobilized on a hard carrier while said immobilization of said pathologic autoantibodies on said hard carrier could be performed by a covalent or non-covalent method either immediately after the sorption on an antigen is completed or after the de- sorption from an antigen
A selective concentration of the donor anti-idiotypic antibodies could also be performed by means of separation of immunocompetent cells from the donor biologic samples, generation of hybπdoma and its further cultivation with separation of the donor anti-idiotypic antibodies The hybπdoma cultivation is performed either outside the animal's body or actually therein
A selective concentration of the donor anti-idiotypic antibodies could also be performed by means of genetic engineering and introducing the genetic structure into the animal's cells
The efficiency of binding the donor immunoglobulins with the pathologic autoantibodies or receptors on the surface of immunocompetent cells is improved by their chemical modification which is preferably provided either by means of binding the additional chemical groups to an antigen molecule or by binding the antibodies to a bio-compatible soluble polymer or by removing a portion of an antibody molecule
The decrease of the content of pathologic autoantibodies in the subject's blood or cerebrospinal fluid is performed by means of an immunosuppressive therapy or by means of selective sorption of autoantibodies from blood or from cerebrospinal fluid By animals there is meant fish, amphibias, reptiles, birds and mammals
To accomplish the above-described methods of treatment necessitating the determination of the presence and of the content of angiogenic factors, a method of investigation of the origins of a malignant process in a subject's body was designed, said method consisting in immobilizing one or a number of antigens, making a biologic preparation, providing the interaction of said preparation with said antigens and defining the presence of autoantibodies against said antigens in said preparation wherein the angiogenic factors are used as antigens The angiogenic factors with a normal or modified due to pathology structure are selected from the group family members like plasminogen and its fragments, e g , angiostatin, collagen-XVIII and its fragments, e g , endostatin, a group of fibroblast growth factors (FGF), placental growth factor of endothelial cells and vascular growth factor of endothelial cells (vascular permeability factor), fibronectin, prolactin, 5 thrombospondin-l and fragments thereof
The artificial structures copying or resembling the antigenic determinants of natural angiogenic factors could be generated for use as an antigen
A biologic preparation could be selected from the group including tissue samplings, blood and its constituents, lymph, cerebrospinal fluid, urea, saliva, lacrimal fluid
I O To accomplish the above-described investigating method a test-system to investigate the origins of pathologic angiogenesis in a subject's body was designed, said system comprising at least one carrier for immobilzation of one or a number of antigens, a biologic preparation and an element for defining the presence of autoantibodies against said antigens in said preparation, wherein the angiogenic factors are used as antigens
15 A test-system element for defining the presence in said preparation of autoantibodies against said antigens is preferably made in the form of revealing reagents or in the form of a direct detection device
Detailed Description of the Invention
Implementation of any of the variants according to claims from 27 to 70 starts from defining the specific angiogenic factors against which the antibodies are produced or from defining the levels that exceed the 0 normal values by using a method of research filed according to claims from 71 to 76 and a test system filed according to claims from 77 to 81
The implementation examples of a test system filed are illustrated in Fig 1 and 2, while the concept of a research method is disclosed in detail in the following non-limiting examples
Fig 1 illustrates an implementation example of a test system in the form of a flexible immune kit (Titertek) 5 with one well of said kit shown as an example Molecules 1 of antigen i e angiogenic factor immobilized on a well 2 of said kit are shown virtually Molecules of just one angiogenic factor could be immobilized throughout the whole of the kit or of various angiogenic factors in the groups of neighboring wells, or of one factor per well
Molecules 3 of autoantibodies contained in a biologic preparation and molecules of secondary (revealing) 0 autoantibodies 4 having a marker are also shown virtually
Fig 2 illustrates an implementation example of a test-system in the form of a set of carrier particles 5 Molecules 1 of an antigen i e angiogenic factor immobilized on particles 5 are shown virtually Molecules of just one angiogenic factor could be immobilized on all particles or of various angiogenic factors on different particles or of several kinds of angiogenic factors on just one particle Molecules 3 of 5 autoantibodies contained in a biologic preparation are also shown virtually Numeral 6 designates antibodies that are non-sorbing on a specific antigen Numerals 7 and 8 designate respectively a tip and a magnetic rod of a magnetic manipulator A reaction is performed in a laboratory vessel 9
Example 1
The wells of a flexible immune kit (Titertek) (See Fig 1 ) were saturated with endostatin (See Fig 1a) and 0 incubated for 30 mm with the samples of the subjects' urea (See Fig 1 b) After thorough rinsing from the urea residues the kits were incubated for 3 hrs at 37° with dissolved in the buffer 1 5 l-labelled goat's polyclonal antibodies against human immunoglobulins in dilution 1 50000 (1 x106 c/min" ml, 50 μl of solution per well) (See Fig 1 c) The kits were 4-5 times rinsed with distilled water After drying during the night at a room temperature the wells were cut out and radioactivity was measured on a Gamma Trac 5 counter To determine the total amount of 125 I- antibodies an aliquot having the volume of 50 μl was calculated from each dilution
Should a radioactivity level exceed at least by 50% the level of control samples, the subject was diagnosed to have angiogenesis disorders related, in particular, to malignant growth Since in the case described an increased content of autoantibodies to endostatin was discovered, it was endostatin that was further used for generating a protein complex in accordance with the present invention
Further use of a prepared protein complex to correct the identified disorders was provided in accordance with the methods filed
Example 2
Preparation of Anqiostatin Complex with Gelonin
Angiostatin (Sigma) (50mg) dissolved in 10 ml of 0,1 M sodium phosphate buffer was mixed with 0 1 ml of 2%gelonιn and then added to the mixture of 0,5 ml of 2% activated copolymer of polyvinyl pyrrolidone and acrolein A conjugation reaction was performed at a room temperature with constant stirring for 2 hrs Separation of low-molecular products was made by dialysis against 0,9% solution of NaCI A protein complex thus produced was used for intravenous injection as a component of a pharmaceutical composition
Generation of Pharmaceutical Composition A solution of a complex produced as described in Example 2 was added with up to 10% of a glucose solution, up to 500 units of heparin and further sterilized by filtration through disposable membrane filters Amicon A sterile solution in sealed bottles was stored at +40C for maximum 5 days until the actual use
The above protein complex could be used in the treatment of diseases with angiogenesis disorders according to claims from 44 to 47 A protein complex thus produced was used for implementing one of the embodiments of the invention filed according to claims from 27 to 43, wherein should an increased content of neutralizing autoantibodies against some angiogenic factor or a group of factors be discovered in a subject's body, a protein complex is prepared and applied, said protein complex comprising the above factor (factors) and means causing the production of immunological tolerance against the above factor (factors) with an immunosuppressive agent used as an immunomodulating portion To achieve the above-set aim it is feasible to generate in a subject's body the state of immunological unresponsiveness (a common name of this state is immunological tolerance) that is using non-toxic methods and substances to selectively suppress the synthesis of autoantibodies against inherent natural protein as in the case described against anti-angiogenic factors or a number of such factors The production of immunological tolerance as a means of suppressing an autoimmune process is widely popular A distinguishing feature of a method filed is that it is proposed to use this customary practice in a new way i e in the prevention and treatment of diseases accompanied by the production of anti-angiogenic antibodies, in particular, malignant ones by the subject's immune system It is proposed to use for this purpose the most optimal combinations of the means of generating the immunological tolerance that have already been successfully used in the experiments for fighting various autoimmune diseases like e g autoimmune encephalomyelitis, diabetes with autoimmune components etc
Immunological tolerance could be achieved either by eliminating the specific clones or by introducing the latter into the state of anergy and not only at the early stages of ontogeny The tolerance depends on the appearance of new kinds of activated lymphocytes and it does not depend on the elimination of the old active ones
According to another embodiment of a method filed, should an increased content of some angiogenic factor/factors be discovered in a subject's body, a protein complex is prepared and applied said protein complex comprising the above factors and means causing the production of neutralizing autoantibodies wherein an immunostimulating agent is used as an immunomodulating portion Example 3
Preparation of Anqiostatin Complex with polymer carπer(Nanopartιcles)
Superparamagnetic nanopaticles Fersar of carbonyl iron (having the diameter from 10 to 50 nm) (Saratov, Russia) covered with polyvinyl alcohol were incubated for 1 hr at a room temperature in the solution of 0, 1 % glutaraldehyde in 0,1 n HCI After thorough rinsing from the acid residues and unbounded aldehyde the particles were added to the solution of angiostatin (Sigma) (100 μg/ml) in 0,02 M sodium phosphate buffer, pH 7,4 and incubated at constant stirring for 12 hrs at +40C A complex with magnetic particles after rinsing from unbounded angiostatin was used for extracorporeal bio-specific hemosorption according to a method as in claims from 48 to 51
5 After an extracorporeal hemosorption an intravenous injection course of a pharmaceutical composition produced as in the Example 3 could be administered
A method filed according to claims from 52 to 70 is implemented in the following way
Firstly the presence of pathologic autoantibodies and/or immunocompetent cells producing said autoantibodies is defined as described e g in the example 1
I O Then the biologic samples of the donors are analyzed, said donors being of the same kind that the animal in question The analysis consists in defining the inhibiting influence of the donor anti-idyotypic antibodies on the interaction of the animal's pathologic autoantibodies with angiogenic factors The choice of a donor/donors is performed on the basis of maximum inhibition by the donor anti-idyotypic antibodies of binding and interaction of the autoantibodies with an antigen The angiogenic factors according to this
15 variant of a treatment method could be either pro- or anti-angiogenic factors
Only anti-idyotypic antibodies could be selected from a biologic sample/samples of the donors chosen
This process could be performed in three different ways
I The concentration of antι-ιdyotypιc antibodies is provided by means of preparative affinity sorption on mammal pathologic autoantibodies immobilized on a carrier 0 The immobilization of pathologic autoantibodies is performed on angiogenic factor already immobilized on a carrier Immobilization of both angiogenic factor and pathologic autoantibodies is performed either by covalent or y non-covalent binding method, however, the combination of the above methods is possible Synthetic ligands could be immobilized on an affinity column instead of autoantibodies with anti-idyotypic antibodies exhibiting an enhanced binding activity in relation to said ligands The substances included into 5 the following groups could be used as such ligands chemical dyes, in particular, dinitrophenol, procion blue and derivatives thereof amino acids, in particular, lysine, arginine, aspartic acid, tyrosine, phenylalanine tryptophan cysteine in D- and L-forms, in the form of monomers and polymers, linear and branched structures and derivatives thereof, 0 - synthetic peptides and derivatives thereof,
- lectins, in particular, lectins from Phaseolus vulgaris, Canavalia ensiformis, πcin, abπn phytohemagglutinin, , clearance lectins,
- nucleic acids, in particular, aptamers and derivatives thereof, oligo or polysaccharides, in particular, heparin, heparan sulpfate dermatan sulphate 5 hyaluronic acid, chitin and derivatives thereof, lipids, in particular, phospholipids and derivatives thereof
The combinations of the above substances are also possible A number of ligands to be used for concentration of anti-idyotypic antibodies is not limited by those listed above
II A selective concentration of anti-idyotypic antibodies could also be performed by means of separating 0 immunocompetent cells producing said anti-idyotypic antibodies from the donors' biologic samples generating a hybridoma and cultivating said hybπdoma with further separation of anti-idyotypic antibodies
In case of antigenic compatibility the cultivation of hybridoma is performed actually inside the animal s body In other cases the cultivation of hybridoma is performed outside the animal s body The cultivation is performed either in the body of an experimental animal or in a cell cultivation reactor
III It is possible to perform a selective concentration of anti-idyotypic antibodies by means of engineering a genetic structure providing a bio-synthesis of a structure having the features of anti-idyotypic antibody and introducing said structure into the animal's cells
Should it be the case, the anti-idyotypic antibodies are actually produced inside the animal's body by its own cells
Anti-idyotypic antibodies could be subjected to chemical modification after their separation with the aim of improving the efficiency of binding with pathologic autoantibodies or receptors on the surface of immunocompetent cells Said modification could be performed as follows binding the additional chemical groups to an antigen molecule, binding the antibodies to a biocompatible soluble polymer, removing a potion of an antigen molecule
The chemical groups bound thereto could belong to various classes, in particular, acyl, ether sulphohydryl, hydroxy/, sulphate, sulphite, carbohydrate, peptide, nucleotide The combinations of chemical groups bound thereto are possible A number of chemical groups bound thereto to increase the efficiency of binding to pathologic autoantibodies or receptors on the surface of immunocompetent cells is not limited by those listed above
Bio-compatible soluble polymers to which antibodies would be bound to could belong to various chemical groups, in particular, starch, inulin, hyaluronic acid, chitin, polylactate, polyglycolate, polyvinyl pyrrolidone copolymer of polyvinyl pyrrolidone and acrolein, polyethylene glycol, polyvinyl alcohol, dextran, and modifications thereof
Binding of anti-idyotypic antibodies to polymers could be both covalent and non-covalent one A number of bio-compatible soluble polymers to which the anti-idyotypic antibodies would be bound to increase the efficiency of binding to pathologic autoantibodies or receptors on the surface of immunocompetent cells is not limited by those listed above
The application of anti-idyotypic antibodies is provided on the background of decreasing the content of pathologic autoantibodies in subject's blood or cerebrospinal fluid The decrease of the content of pathologic autoantibodies is provided either by means of an immunosuppressive therapy or by means of selective sorption of autoantibodies from blood or cerebrospinal fluid
Thus, a method filed provides for a specific treatment of diseases with angiogenesis disorders The indications for application of specific anti-idyotypic antibodies are extending, and, moreover, the specific anti-idyotypic antibodies thus produced are characterized by increased efficiency and improved tolerance on the part of the patient

Claims

1_ A protein complex comprising an antigen and attached thereto effector portion with immunomodulating activity, wherein said antigen presents an angiogenic factor 2 A protein complex as in claim 1 , wherein said portion with immunomodulating activity presents an immunostimulator
3 A protein complex as in claim 1 , wherein said portion with immunomodulating activity presents an immunosuppressor
4 A protein complex as in claim 1 , wherein said angiogenic factor is made so that it interacts with immunocompetent cells belonging to the specific clones of B-lymphocytes and plasma cells that are the derivatives thereof and also with T-lymphocytes
5 A protein complex as in claim 1 , wherein said antigenic portion is made in the form of an artificial structure copying or resembling the antigenic determinants of natural angiogenic factors
6 A protein complex as in claim 3, wherein said immunosuppressor of said protein complex presents or monoclonal antibodies against the surface receptors of immunocompetent cells, or a toxin selected from the group including the toxins of bacterial, plant, animal, fungal or virus origin or a medication of cytotoxic action
7 A protein complex as in claim 3, wherein said immunosuppressor of said protein complex presents a combination of monoclonal antibodies, toxins and medications 8 A protein complex as in claims 6 or 7, wherein said monoclonal antibodies can be selected from the groups including anti CD3, anti CD4, anti CD19, antιCD20, anti CD21 , anti CD22, anti CD23 anti CD40 and anti CD80
9 A protein complex as in claims 6 or 7, wherein said toxin presents a bacterial toxin
10 A protein complex as in claims 6 or 7, wherein said medication could be specifically selected from groups related to kalicheamycin, thiotepa, taxan, nitrous ypeπte, ethylene imine, alkyl sulfonate, triazene taxol, kamptotecin, azaseπne, tamoxifen, dolastine/auπstatine, haemiasterlin and maitanzinoid ethoposide, procarbazine, carmustine, phenyl butyrate, brιostatιne-1 , leucovorin enzymes, Vinca alkaloids, antιbιotιcs(ιncludιng dien antibiotics anthracyclines anthramycins), purine, pyrimidine azathiopnne, cyclospoπne, penicilamine, chloroquine methotrexate, cyclophosphamide, methylhydrazine cisplatin, , prednisone, COX 2 inhibitors, salicylates, para-aminophenol, indole indene, heteroarylacetic acids, arylpropionic acids anthranilic acids enolic acids, alkanons, 2,3-dιphenyltetrahydrofuran nitrosourea, folic acid and also from the combinations of substances of several chemical groups, groups of origin and groups.according to mechanism of action
11 A protein complex as in claim 1 , wherein said angiogenic factor is a pro-angiogenic one 12 A protein complex as in claim 1 , wherein said angiogenic factor is an anti-angiogenic one
13 A protein complex as in claim 12, wherein said pro-angiogenic factors are selected from the group including the groups of fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukines, platelet-derived growth factors, angiopoetins, tumor-necrosis factors, matrix metalloproteinases and, in particular from transforming growth factor beta 1 intercellular adhesion molecule 1 , hepatocyte growth factor, nerve growth factor, connective tissue growth factor, tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor-1 , thymidine-phosphorylase
14 A protein complex as in claim 1 , wherein said protein complex is made in the form of an immunoglobulin-like structure, in which fragment of variable domen is identical to fragment of an angiogenic factor, while a constant domen of an immunoglobulin-like structure acts as immunosuppressor 15 A protein complex comprising an antigen and an effector portion bound thereto to provide the specific influence on a target, cell, wherein said antigen presents an angiogenic factor
16 A protein complex as in claim 15, wherein said anti-angiogenic factors could be selected from the group comprising members of families like inteferons, tissue inhibitors of metalloproteinases, fibroblast growth factors, placental endothelial growth factors, vascular endothelial growth factors plasminogen collagen, fibronectin, prolactin, growth hormone, placental lactogen , thrombospondin and fragments thereof
17 A protein complex as in claim 15, wherein said angeogenic factors are made in the form of an artificial structure copying or resembling the antigen determinants of natural anti-angiogenic factors 18 A protein complex as in claim 15, wherein said effector portion presents a toxin selected from the group including the toxins of bacterial, plant, animal, fungal or virus origin, cytotoxic antibiotics ions of heavy metals in various forms, photosensitazers, radionuclides or the combinations thereof
19 A protein complex comprising an antigen immobilized on an effector portion in the form of a polymer carrier, wherein said antigen presents an angiogenic factor 20 A protein complex as in claim 19, wherein said angiogenic factor is either a pro- or anti-angiogenic one
21 A protein complex as in claim 20, wherein said pro-angiogenic factors could be selected from the group including members of families like fibroblast growth factors, vascular endothelial growth factors, colony stimulating factors, interleukines, platelet-derived growth factors, angiopoetms, tumor-necrosis factors, matrix metalloproteinases and, in particular, transforming growth factor beta 1 , intercellular adhesion molecule 1 , hepatocyte growth factor, nerve growth factor, connective tissue growth factor, tenascin-R, prolactin, growth hormone, placental lactogen, insulin-like growth factor-1 , thymidine- phosphorylase
22 A protein complex as in claim 20, wherein said anti-angeoginic factors could be selected from the group including members of families like inteferons, tissue inhibitors of metalloproteinases fibroblast growth factors, placental endothelial growth factors , vascular endothelial growth factors plasminogens collagens, fibronectins, prolactins, growth hormones, placental lactogens, thrombospondins and fragments thereof
23 A protein complex as in claims 19 or 20, wherein said angiogenic factors are made in the form of an artificial structure copying or resembling the antigen determinants of natural pro- or anti-angiogenic factors
24 A protein complex as in claim 19, wherein the polymer carriers could be selected from the group comprising polymer particles, both magnetic and non-magnetic ones, continuous and hollow fibers single-layer or multi-layer membranes 25 Use of protein complexes according to claims from 1 to 13 for prevention and treatment of diseases with angiogenesis disorders
26 Use of protein complexes according to claims from 14 to 24 for treatment of diseases with angiogenesis disorders
27 A method for prevention and treatment of diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex containing an antigen portion and an immunomodulating portion, wherein a) the content of an angeoginic factor/factors in the subject's biologic fluids is pre-defined and the factors exceeding the existing norms are determined, b) a kind/kinds of angiogenic factors are defined against which the patient's body produces elevated levels of autoantibodies, c) a protein complex is produced, said protein complex containing the identified angiogenic factors as an antigenic portion and an immunomodulating portion, and d) said protein complex is administered for modulating an immune response to said angeoginic factors
28 A method as in claim 27, wherein said protein complex includes one or a number of angeoginic factors
29 A method as in claim 27, wherein an immunomodulating portion of said protein complex presents an 5 immunostimulator
30 A method as in claim 27, wherein an immunomodulating portion of said protein complex presents an immunosuppressor
31 A method as in claim 27, wherein said protein complex is administered intravenously, intraarterial^ intramascular, intraosseous, intrafascial, intralumbar, hypodermic, intraorganic and also to the mucous
I O membranes, e g , conjunctiva, intranasal, intratracheal, intrabronchial, intraalveolar intravaginal intrauteral, per os, per rectum
32 A method as in claim 27, wherein the administration of said protein complex is performed regularly with the periodicity from 1 to 48 hours, preferably with the periodicity of 24 hours
33 A method as in claim 27, wherein said diseases with angiogenesis disorders are selected from the 15 following groups including cardiovascular diseases,, respiratory diseases,, urinary tract diseases, gastrointestinal truct diseases 0 reproductive dysorders, nervous system diseases, mental dysorders, musculoskeletal system diseases, endocrine diseases, 5 connective tissue diseases, skin diseases, neoplastic diseases, transplantation diseases, diseases related to sense organs, 0 infectious diseases,
34 A method as in claim 27, wherein said protein complex is produced so that its effector portion presents a polymer carrier with an antigen in the form of an angiogenic factor immobilized thereon,
35 A method as in claim 34, wherein said polymer carrier is selected from the group including polyvinyl pyrrolidone and copolymer with acrolein, polyethylene glycol, polyvinyl alcohol, dextran, phycoll 5 36 A method as in claim 27, wherein said angiogenic factor is a pro-angiogenic one
37 A method as in claim 27, wherein said angiogenic factor is an anti-angiogenic one
38 A method as in claims 36 and 37, wherein said angiogenic factor is produced so that it interacts with immunocompetent cells belonging to the specific clones of B-lymphocytes and to the plasma cells that are derivatives thereof, and also withT-lymphocytes 0 39 A method as in claim 27, wherein said angiogenic portion is made in the form of an artificial structure copying or resembling the antigenic determinants of natural angiogenic factors
40 A method as in claim 30, wherein said immunosuppressor of said protein complex presents the monoclonal antibodies against the surface receptors of the immunocompetent cells and a toxin selected from the group including the toxins of bacterial, plant, animal, fungal or viral origin or a medication of 5 cytotoxic action
41 A method as in claim 30, wherein said immunosuppressor presents a combination of monoclonal antibodies, toxins and medications 42 A method as in claims 40 and 41 , wherein said monoclonal antibodies could be selected from the groups including anti CD3, anti CD4, anti CD19, antιCD20, anti CD21 anti CD22, anti CD23, anti CD40 and anti CD80
43 A method as in claims 40 and 41 , wherein said toxin presents a bacterial toxin
5 44 A treatment method for diseases with angiogenesis disorders consisting in the administration of an effective dose of a pharmaceutically active substance in the form of a protein complex comprising an angiogenic factor and an effector portion, wherein a kind/kinds of angiogenic factors against which a subject's body exhibits the autoantibodies is pre-defined, a protein complex containing an identified angiogenic factor is produced, and said protein complex is used to completely eliminate from said
I O subject's body said autoantibodies and/or the cells-producers thereof
45 A method as in claim 44, wherein said protein complex is produced so that its effector portion is intended for a specific influence on a target cell, while said influence is provided by introducing said complex into a subject's body
46 A method as in claim 45, wherein said protein complex is administered intravenously, intraarterial, 15 intramasculary, intraosseously, hypodermally, intraorganic, intrafascialy, intralumbally, per os, per rectum
47 A method as in claim 45, wherein said diseases with angiogenesis disorders are selected from the following groups of diseases including cardiovascular diseases, respiratory diseases, 0 urinary tract diseases, gastrointestinal truct diseases, reproductive dysorders, nervous system diseases, mental dysorders, 5 musculoskeletal system diseases, endocrine diseases, connective tissue diseases, skin diseases, diseases related to sense organs 0 neoplastic diseases, transplantation diseases, infectious diseases and the complications thereof
48 A method as in claim 44, wherein said protein complex is produced so that its effector portion presents a polymer carrier with an antigen immobilized thereon, while its influence is effected by means 5 of bio-specific sorption of the patient's biologic fluid
49 A method as in claim 48, wherein said angiogenic factor is either a pro- or anti-angiogemc one
50 A method as in claim 48, wherein said method according to claims from 48 to 50 is performed either simultaneously or after the sorption process is completed
51 A method as in claims from 48 to 50, wherein blood, blood plasma, lymph, cerebrospinal fluid and/or 0 bone marrow are used as a biologic fluid
52 A treatment method for diseases with angiogenesis disorders in animals consisting in effecting the pathologic autoantibodies present in an animal's body and/or the cell-producers of said autoantibodies by a medication of intravenous immunoglobulin, and further consisting in the selection of intravenous immunoglobulins reacting with the autoantibodies characteristic of a specific disease, and administration 5 of selected immunoglobulins to the animal, wherein said pathologic autoantibodies are the antibodies against the angiogenic factors, while the presence of said pathologic autoantibodies and/or of the respective immunocompetent cells is defined directly in a biologic sample of said animal, and the anti- idiotypic antibodies that are used as immunoglobulins are taken from a donor/donors of the same biologic type so that their anti-idiotypic antibodies would most efficiently react with the pathologic 0 autoantibodies with the donor anti-idiotypic antibodies obtained from said donor/donors being selectively concentrated 53 A method as in claim 52, wherein the presence of autoantibodies is defined by analyzing the interaction of a wide range of antigens immobilized on the carries with a sample/samples of the animal's biologic samples with further analysis of the quantity and quality of antoantibodies having bound to antigens 54 A method as in claim 53, wherein said antigens immobilized on the carriers are mainly related to angiogenic factors
55 A method as in claim 53, wherein the structures that are immunoidentical to antigens are used as antigens immobilized on the carriers
56 A method as in claim 53, wherein blood samples and its constituent parts, cerebrospinal fluid saliva, urea, phlegm, mucus and tissue samplings are used as animal's biologic samples
57 A method as in claim 53, wherein the analysis of the quantity and the quality of autoantibodiesis is performed by the following methods including enzyme-linked immuno absorption assay(ELISA) radioimmunoassay (RIA), immunofluorescence assay, electrophoresis, chromatography, mass spectrometry, light microscopy, atomic-force microscopy, plasmon resonance or the combinations thereof
58 A method as in claim 52, wherein the choice of a donor/donors is performed on the basis of a maximum inhibition by the donor anti-idiotypic antibodies of binding and interaction of said autoantibodies to said antigen
59 A method as in claim 52, wherein a selective concentration of donor anti-idiotypic antibodies is provided by means of an affinity sorption of the animal's pathologic autoantibodies immobilized on the carrier
60 A method as in claim 59, wherein said immobilization of said pathologic autoantibodies on said carrier is performed by a covalent or non-covalent binding
61 A method as in claim 59, wherein said immobilization of said pathologic autoantibodies on said carrier is performed immediately after the sorption on said antigen
62 A method as in claim 59, wherein said immobilization of said pathologic autoantibodies on said carrier is performed immediately after the desorption from an antigen
63 A method as in claim 52, wherein said selective concentration of the donor anti-idiotypic antibodies is performed by means of separation from the biologic samples of the donor immunocompetent cells, generation of hybridoma and its further cultivation with separation of the donor anti-idiotypic antibodies
64 A method as in claim 63, wherein said hybridoma cultivation is performed outside the animal's body
65 A method as in claim 63, wherein said hybridoma cultivation is performed inside the animal's body
66 A method as in claim 52, wherein said selective concentration of the donor anti-idiotypic antibodies is performed by means of genetic engineering of the corresponding nucleic acid structure and introducing said structure into the animal's cells
67 A method as in claim 52, wherein the binding efficiency of donor immunoglobulins with the pathologic autoantibodies or receptors on the surface of immunocompetent cells is improved due to their chemical modification
68 A method as in claim 67, wherein said chemical modification is provided either by means of binding the additional chemical groups to an antigen molecule or by binding said antibodies to a bio-compatible soluble polymer or by removing a portion of an antibody molecule
69 A method as in claim 52, wherein the decrease of the content of pathologic autoantibodies in a subject's blood or cerebrospinal fluid is provided by means of an immunosuppressive therapy or by means of a selective sorption of autoantibodies from blood or from cerebrospinal fluid 70 A method as in any of the preceding claims, wherein said animals are fish, amphibias reptiles, birds and mammals
71 A method of investigating the origins of angiogenesis disorders in a subject's body consisting in immobilizing one or a number of antigens, making a biologic preparation, providing the interaction of said preparation with said antigens and defining the presence in said preparation of autoantibodies against said antigens, wherein the angiogenic factors are used as antigens
72 A method as in claim 71 , wherein said angiogenic factors are selected either with a normal or modified due to pathology structure
73 A method as in claim 72, wherein said angiogenic factors are selected from the group of family members like plasminogens, , collagens, , fibroblast growth factors (FGF), placental endothelial growth factors, vascular endothelial growth factors, , fibronectins, prolactins, thrombospondins and fragments thereof
74 A method as in claim 71 , wherein said artificial structures are generated to be used as an antigen said structures copying or resembling the antigenic determinants of natural angiogenic factors 75 A method as in claim 71 , wherein said biologic preparation is selected from the group including tissue samplings, blood and its constituents, lymph, cerebrospinal fluid, urea, saliva, lacrimal fluid
76 A test-system for investigating the origins of angiogenesis disorders in a subject s body comprising at least one carrier for immobilzation of one or a number of antigens, a biologic preparation and an element for defining the presence in said preparation of said autoantibodies against said antigens, while the angiogenic factors are used as antigens
77 A test-system as in claim 76, wherein said angiogenic factors are the factors with a normal structure or modified due to pathology structure
78 A test-system as in claim 77, wherein said angiogenic factors are selected from a group of family members like plasminogens, , collagens, , fibroblast growth factors (FGF), placental endothelial growth factors, vascular endothelial growth factors, , fibronectins, prolactins, thrombospondins and fragments thereof
79 A test-system as in claim 76, wherein said test system contains some artificial structures copying or resembling the antigenic determinants of natural angiogenic factors
80 A test-system as in claim 76, wherein said biologic preparation is selected from the group including tissue samplings, blood and its constituents, lymph, cerebrospinal fluid, urea, saliva, lacrimal fluid
81 A test-system as in claim 76, wherein an element for defining the presence in said preparation of autoantibodies against said antigens is made in the form of revealing reagents or in the form of a direct detection device
PCT/BY2007/000002 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders WO2008006187A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
BYA20060719 2006-07-12
BY20060719 2006-07-12
BYA20060916 2006-09-20
BY20060916 2006-09-20
BY20061352 2006-12-28
BYA20061352 2006-12-28
BY20070027 2007-01-12
BYA20070027 2007-01-12

Publications (2)

Publication Number Publication Date
WO2008006187A2 true WO2008006187A2 (en) 2008-01-17
WO2008006187A3 WO2008006187A3 (en) 2009-02-12

Family

ID=38805594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BY2007/000002 WO2008006187A2 (en) 2006-07-12 2007-07-12 Protein complexes for prevention and treatment of diseases with angiogenesis disorders

Country Status (1)

Country Link
WO (1) WO2008006187A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117040A1 (en) * 2009-04-10 2010-10-14 富士フイルム株式会社 Five-membered heterocyclic compound
US20100310626A1 (en) * 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
CN110105362A (en) * 2019-05-29 2019-08-09 威海中腾医药科技有限公司 A kind of folic acid synthetic method of the safe green of heteropoly acid catalysis
CN115427041A (en) * 2020-04-20 2022-12-02 格兰尼斯制药公司 Oral delivery system comprising hydroxychloroquine and/or chloroquine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451312B1 (en) * 1992-03-05 2002-09-17 Board Of Regents, The University Of Texas System VEGF-gelonin for targeting the vasculature of solid tumors
CN1114685A (en) * 1994-11-09 1996-01-10 北京医科大学 Human interleukin-2 immunotoxin
WO1999045018A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
WO2003106487A1 (en) * 2002-06-17 2003-12-24 Protherics Plc Immunogenic conjugates
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
WO2006031353A2 (en) * 2004-08-16 2006-03-23 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOTZ HUBERT G ET AL: "Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer." JOURNAL OF GASTROINTESTINAL SURGERY, vol. 6, no. 2, March 2002 (2002-03), pages 159-166, XP002492441 ISSN: 1091-255X *
KRAUSS JÜRGEN ET AL: "Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme" BRITISH JOURNAL OF HAEMATOLOGY, vol. 128, no. 5, 1 March 2005 (2005-03-01), pages 602-609, XP002463022 ISSN: 0007-1048 *
RAMAKRISHNAN S ET AL: "VASCULAR ENDOTHELIAL GROWTH FACTOR-TOXIN CONJUGATE SPECIFICALLY INHIBITS KDR/FLK-1-POSITIVE ENDOTHELIAL CELL PROLIFERATION IN VITRO AND ANGIOGENESIS IN VIVO" CANCER RESEARCH, vol. 56, no. 6, 1 January 1996 (1996-01-01), pages 1324-1330, XP001247100 ISSN: 0008-5472 *
WILD R ET AL: "INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH BY VEGF121-TOXIN CONJUGATE: DIFFERENTIAL EFFECT ON PROLIFERATING ENDOTHELIAL CELLS" BRITISH JOURNAL OF CANCER, vol. 83, no. 3, 1 January 2000 (2000-01-01), pages 1077-1083, XP002408273 ISSN: 0007-0920 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100310626A1 (en) * 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
WO2010117040A1 (en) * 2009-04-10 2010-10-14 富士フイルム株式会社 Five-membered heterocyclic compound
CN110105362A (en) * 2019-05-29 2019-08-09 威海中腾医药科技有限公司 A kind of folic acid synthetic method of the safe green of heteropoly acid catalysis
CN115427041A (en) * 2020-04-20 2022-12-02 格兰尼斯制药公司 Oral delivery system comprising hydroxychloroquine and/or chloroquine

Also Published As

Publication number Publication date
WO2008006187A3 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
JP6999601B2 (en) Therapeutic delivery vesicles
CN107001459B (en) anti-AGE antibodies for the treatment of inflammatory and autoimmune disorders
US20130017205A1 (en) Inhibition of AXL Signaling in Anti-Metastatic Therapy
JP7434328B2 (en) Antibodies that bind to citrullinated histones 2A and/or 4
CN106103479A (en) Identify anti-chemotactic factor for eosinophils 2 antibody of other CCR3 binding chemotactic factors
CN114230663B (en) Antibodies to TrkA and uses thereof
WO2018156649A1 (en) Compositions of t cell modulator (tcm) molecules and uses thereof
US8734775B2 (en) Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
WO2022194311A2 (en) Il-17ra antibody fc fusion protein, and use thereof
WO2008006187A2 (en) Protein complexes for prevention and treatment of diseases with angiogenesis disorders
JP2022512735A (en) Compositions and Methods for Treating Liver Disease
US10456466B2 (en) Anti-VEGF antibody
WO2023217020A1 (en) Vκ4-1-IGLC POLYPEPTIDE AND USE THEREOF
JP2019521963A (en) Agents that activate CD47 and their use in treating inflammation
CN104379165A (en) Therapeutic agent for inflammatory disease
CN113912712B (en) Preparation and application of monoclonal antibody for resisting alpha-synuclein
WO2022171195A1 (en) Treatment of gastric cancer by using anti-cd87 antibody in combination with anti-pd1 antibody
US20210403897A1 (en) Chemical engineering of erythrocytes to display polypeptides and other biomacromolecules
US20100184695A1 (en) Vascular endothelial cell-binding peptide
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
US20240024418A1 (en) Method for treating cancer and inflammatory diseases using stem cell- derived extracellular vesicles comprising sirp
CA2351585A1 (en) Influencing of angigenesis using cd66a
JP2022102523A (en) Peptides and use thereof
CN104163870B (en) Recombinant protein of specific antagonist TNF alpha signal paths of joint targeting and application thereof
CN116925226A (en) anti-MSLN antibodies, methods and uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07800404

Country of ref document: EP

Kind code of ref document: A2